RecruitingNot ApplicableNCT07182240
Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas
Sponsor
Roswell Park Cancer Institute
Enrollment
60 participants
Start Date
Dec 22, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
To assess the feasibility and provide information on the utility of noninvasive line field confocal optical coherence tomography (LC-OCT) for the presurgical assessment of Mohs micrographic surgery sites in patients undergoing removal of cutaneous basal cell carcinomas (BCC).
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age ≥ 18 years
- Participant must understand the investigational nature of this study and provide written consent prior to receiving any study-related procedure.
- Participant must be clinically eligible for Mohs surgery as determined by their referring dermatologist and the Mohs surgeon.
- The participant must have a BCC with superficial histology or a BCC with multiple histological features that also include superficial histology, which is appropriate for Mohs surgery.
Exclusion Criteria4
- Known or reported allergy to mineral oil, the optical agent used during imaging.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Any condition which in the investigator's opinion deems the subject an unsuitable candidate to undergo imaging procedure.
- Unwilling or unable to follow protocol requirements
Interventions
DEVICELC-OCT Imaging
handheld imaging device will take high resolution images of lesion
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07182240
Related Trials
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
NCT0434943628 locations
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
NCT066244753 locations
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
NCT072850441 location
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
NCT058590747 locations
Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy
NCT050209121 location